New Drug Application News and Research

RSS
Reversal of ADAR1 hyper-editing with small molecule inhibitor

Reversal of ADAR1 hyper-editing with small molecule inhibitor

UC Davis launches new center to accelerate the development of promising cancer therapies

UC Davis launches new center to accelerate the development of promising cancer therapies

Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient

Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient

Combination treatment improves outcomes in advanced kidney cancer patients

Combination treatment improves outcomes in advanced kidney cancer patients

Developments in Engineered T Cells for Type 1 Diabetes

Developments in Engineered T Cells for Type 1 Diabetes